Figure 1
Figure 1. Comparison of CML and lymphoid blast crisis models. Lin− cells from bone marrow of wild-type, p16INK4A/p19ARF-null, or p19ARF-null donors were isolated as described in “Generation of murine models.” The cells were transduced with vectors coexpressing p210BCR/ABL and EGFP, followed by injection into sublethally irradiated wild-type recipient mice. Leukocytes from peripheral blood of the recipients were collected for lineage and morphological analysis approximately 2 to 3 weeks after transplantation. (A) Expression of p210BCR/ABL in wild-type donors resulted in the development of CML-like disease in recipients. Histological staining of peripheral blood shows mature granulocytes (G), FACS analysis indicates that almost all EGFP+ cells are Mac1+/Gr1+. (B) Injection of p210BCR/ABL-expressing cells from p16INK4A/p19ARF or p19ARF-null donors showed high levels of immature lymphoblasts (LBs) in recipient mice. The immunophenotype of EGFP+ cells is almost entirely B220+/CD19+, indicating the disease type is B-lineage acute lymphoblastic leukemia (B-ALL).

Comparison of CML and lymphoid blast crisis models. Lin cells from bone marrow of wild-type, p16INK4A/p19ARF-null, or p19ARF-null donors were isolated as described in “Generation of murine models.” The cells were transduced with vectors coexpressing p210BCR/ABL and EGFP, followed by injection into sublethally irradiated wild-type recipient mice. Leukocytes from peripheral blood of the recipients were collected for lineage and morphological analysis approximately 2 to 3 weeks after transplantation. (A) Expression of p210BCR/ABL in wild-type donors resulted in the development of CML-like disease in recipients. Histological staining of peripheral blood shows mature granulocytes (G), FACS analysis indicates that almost all EGFP+ cells are Mac1+/Gr1+. (B) Injection of p210BCR/ABL-expressing cells from p16INK4A/p19ARF or p19ARF-null donors showed high levels of immature lymphoblasts (LBs) in recipient mice. The immunophenotype of EGFP+ cells is almost entirely B220+/CD19+, indicating the disease type is B-lineage acute lymphoblastic leukemia (B-ALL).

Close Modal

or Create an Account

Close Modal
Close Modal